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Abstract
Introduction: The NCEP III -ATP guidelines provide clear clinical directives for lipid management
especially statins therapy in appropriate patient groups. Compliance of primary care physicians with
these guidelines especially in ambulatory care settings has been shown to be poor. The compliance
of cardiologist to these guidelines is less documented.
Methods: A retrospective chart review of 386 patients managed in a large urban cardiology
practice was undertaken. Patients with documented contraindications to use of statins were
excluded from the study. Only patients with two or more years of follow-up in the practice were
included. Demographic variables and medical history including CAD or its equivalent and its major
risk factors were identified. The proportion of patients on statins and adequacy of statins therapy
were recorded. The lipid profiles of all patients were also analyzed.
Results: Fifteen patients with documented contraindications to statins therapy including
persistent/severe LFT abnormalities, allergies, and gastrointestinal intolerance were excluded. A
total of 371 patients were included in the analysis. The mean age for patients in the study was 65
years (range: 42–84). 236 (64%) were males while 141 (36%) were females. 161 (43%) patients were
on statins while 210 (57%) weren't. 88 (62%) of females were on stain compared to 116 (49%) of
males (p = 0.001). 68% of patients below the age of 50 yrs were not on statins compared with 55%
of those greater than 50 yrs (p = 0.01). 38% of patients on statins therapy had sub-optimal lipid
profile despite greater than two years of therapy. No statistically significant differences in race and
use of satins were noted.
Conclusion: This study demonstrates a higher than expected prevalence of sub-optimal
management of dyslipidemia among patients with established coronary heart disease without
contraindications to statins managed by cardiologists. Cardiology and primary care practices
require similar comprehensive routine lipid management program that is assiduously maintained
and evaluated at both in-patient and out patient settings to ensure most patients receive optimal
therapy with statins and other lipid lowering agents.
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HMG-CoA reductase inhibitors (Statins) are used widely
for the treatment of hypercholesterolemia. They inhibit
HMG-CoA reductase competitively; reduce LDL levels
more than other cholesterol-lowering drugs, modestly
increase HDL, and lower triglyceride levels in hypertriglyc-
eridemic patients. Statins are well tolerated and have an
excellent safety record [1-5].
Clinical trials in patients with and without coronary heart
disease and with and without high cholesterol have dem-
onstrated consistently that statins reduce the relative risk
of major coronary events by [almost equal to] 30% and
produce a greater absolute benefit in patients with higher
baseline risk [2,5,6]. Proposed mechanisms include favo-
rable effects on plasma lipoproteins, endothelial function,
plaque architecture and stability, thrombosis, and inflam-
mation. Mechanisms independent of LDL lowering may
play an important role in the clinical benefits conferred by
these drugs and may ultimately broaden their indication
from lipid-lowering to anti-atherogenic agents [6].
The National Cholesterol Education Program (NCEP)
released its third Adult Treatment Report in 2001. This
report once again recommended a low-density lipopro-
tein (LDL-C) level lower than 100 mg/dL for all patients
with coronary artery disease its equivalent. Trials demon-
strating a 22% to 42% reduction in risk of fatal coronary
heart disease (CHD) with the use of cholesterol treatment
support the NCEP recommendation that patients with
CHD and other forms of atherosclerosis be treated to an
LDL-C goal level lower than 100 mg/dL [7,8].
Despite continued physician and public education, treat-
ment goals for individuals with CHD are not being met.
Multiple surveys assessing physician compliance with the
guidelines have found only 11% to 25% of patients with
CHD at the recommended LDL-C goal [9,10]. A review of
the National Registry of Myocardial Infarction reported
that in the year 2000 only 31.7% of more than 130,000
patients discharged with the diagnosis of acute myocar-
dial infarction were prescribed cholesterol medications
[11].
Unfortunately, this public health problem is not limited
to the United States. A two-part survey of nine European
countries known as EUROASPIRE found that although
cholesterol medications use had increased from 21% to
49% among patients with hyperlipidemia, most patients
with CHD were not at goal cholesterol levels [12,13]. Our
study was designed to assess the compliance of cardiolo-
gists to the NCEP III guidelines in an ambulatory care set-
ting.
Methods
A retrospective chart review of 386 patients managed in a
large urban cardiology practice was undertaken. Patients
with documented contraindications to use of statins were
excluded from the study. Only patients with two or more
years of follow-up in the practice were included. Demo-
graphic variables and medical history including CAD or
its equivalent and its major risk factors for CAD were iden-
tified. The proportion of patients on statins and adequacy
of therapy with statins was recorded. The lipid profiles of
all patients were also reviewed.
Results
Fifteen patients with documented contraindications/
intolerance to statins including persistent/severe LFT
abnormalities, allergies, and gastrointestinal intolerance
were excluded. A total of 371 patients were included in the
analysis. The mean age for patients in the study was 65
years (range: 42–84). 236 (64%) were males while 141
(36%) were females. 161 (43%) patients were on statins
while 210 (57%) weren't. 88 (62%) of females were on
statins compared to 116 (49%) of males (p = 0.001). 68%
of patients below the age of 50 yrs were not on statins
compared with 55% of those greater than 50 yrs (p =
0.01). 38% of patients on statins therapy had sub-optimal
lipid profile despite greater than two years of therapy. No
statistically significant difference in race and adequacy of
therapy with statins was noted.
Discussion
Evidence suggests that cholesterol treatment, particularly
with statins, provide the largest event reductions associ-
ated with any of the medication interventions after CHD
events. A randomized controlled trial found that patients
with acute coronary syndromes who received atorvastatin
within 96 hours of admission had a significantly lower
risk of symptomatic ischemia with emergency re-hospital-
ization during 16 weeks of follow-up evaluation [13].
Additionally, a prospective Swedish study demonstrated a
reduction in 1-year mortality when patients were dis-
charged with a statins after an acute myocardial infarction
[5]. Statins and other cholesterol medications also have
anti-inflammatory action and beneficial effects on
endothelial function, independent of cholesterol levels
[15,16].
The reasons for the persistent poor physician compliance
with lipid lowering guidelines are unclear. Strategies for
improving physician compliance with the NCEP III guide-
lines include identifying high risk patients, calculating
global risks, determining goals, initiating therapy, moti-
vating and educating patients and physicians to maintain
compliance and patient/ physician tracking of progress.
Other strategies include teaching physicians to implement
lipid treatment strategies, using reminders to promptlyPage 2 of 4
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ing patients advocate such as a nurse case manager to help
deliver to prompt care [7,8].
The many patients discharged without prescriptions for
statins may either be lost to medical follow-up or do not
eventually receive prescriptions for statins from their pri-
mary care providers. The Third Report of the Expert Panel
on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (ATP III), which constitutes the
updated clinical guidelines of the National Cholesterol
Education Program (NCEP), recommends that lipid-low-
ering drug therapy be initiated at hospital discharge [7,8].
The NCEP ATP III also provides important information
on the goals of lipid-lowering therapy in patients after
ACS. The challenge for the specialist is to establish a pre-
discharge plan that includes maximal dosing to achieve
aggressive target goals and to work with the patient's pri-
mary care provider to maintain these goals long-term.
A great deal of attention has been focused on the poor
adherence of primary care physicians to adequate therapy
with statins and the NCEP-ATP guidelines. Cardiologists
intuitively appear to be more aggressive in managing dys-
lipidemia especially among patients with CAD or its
equivalent. The finding of poor compliance with the
NCEP III guidelines in a pure cardiology based practice
fully affiliated with a very active internal medicine resi-
dency program is therefore unexpected. This study dem-
onstrates only 43% of patients (all with documented
coronary heart disease) in this practice were on statins and
of those on statins only 62% were at target goal of the LDL
cholesterol, HDL cholesterol and triglycerides despite two
or more years of follow up. This demonstrates a global
poor performance by urban cardiologist. Reasons for this
poor physician specialist compliance are hard to advance.
Health care financing and medical insurance coverage
always play a cardinal role in determining compliance to
medications on both the side of physicians and patients.
All patients in this study had medical insurance coverage
for there general medical care. A particularly important
factor to consider however is the lack of prescription cov-
erage for patients on Medicare (those above the age of 65).
The mean age for patients in this study was 65 years and
42% of patients were above the age of 65. These elderly
patients are more likely to have multiple co-morbid con-
ditions, already spending a sizable part of there meager
income on several other medications and therefore una-
ble to afford the cost of statins. A few cardiologists have
expressed concern related to this. In this practice, a sizable
number of patients are on "samples" of statins provided
by various drug companies at no cost to the patients. The
supply of these samples is rather erratic and might lead to
frequent change of various types of statins depending on
availability. The statistically significant lower proportion
of patients above the age of 50 years who were on statins
further confirms this assertion. Additionally, the study
further demonstrates females were more likely to be on
statins compared to males regardless of the age groups
considered. A probable explanation is the increasing fre-
quency with which women ask about their test results and
"cholesterol" and is what is been done about it. The role
of media campaigns especially television commercials on
"ask you doctor" about various medications and diseases
might contribute to the active involvement of more
women than men on their health care and more women
asking why or why not they should be on such medica-
tions.
Conclusion
Our findings demonstrate a high prevalence of sub-opti-
mal management of dyslipdemia among patients without
clear contraindication to use of statins managed by cardi-
ologists. The poor compliance with the NCEP III guide-
lines persists even in patients with recent myocardial
infarction. Our study therefore suggests that patients with
CHD might not necessarily get to target LDL-C, HDL-C
and triglycerides goal levels even when managed in a pure
cardiology specialty practice. A routine discharge or dis-
ease management program that is assiduously maintained
and evaluated at both in in-patient and out patient set-
tings is needed to ensure most patients receive optimal
cholesterol therapy notably with statins. If these findings
are placed within context of the findings of the recent
TIMI 22 study which indicate that patients with recent
myocardial infarction benefit from early and continued
lowering of LDL cholesterol to levels substantially below
current target levels, the challenges of implementation
becomes even more enormous and the prospects for
excellent compliance with the standard of care for lipid
management appear rather dismal without concerted
efforts by patients, and all relevant health care providers
and their associates[17,18]. Swift national health policy
changes that would incorporate adequate prescription
coverage are needed also to ease the hardship of cost of
medications especially among elderly patients. Physicians
must also actively engage (albeit the limitation of time) in
soliciting for medication assistance programs and favora-
ble health care policy changes on behalf of their patients
from pharmaceutical companies and the various tiers of
government.
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